The Juravinski Cancer Centre is a comprehensive centre for cancer care and cancer research in Hamilton, Ontario, Canada. Operated by Hamilton Health Sciences, it is adjacent to the Juravinski Hospital, which provides emergency department facilities.

There are 125 beds in Juravinski Cancer Centre.

During the past decade, Juravinski Cancer Centre conducted 187 clinical trials. In the 10-year time frame, 187 clinical trials started and 111 clinical trials were completed, i.e. on average, 59.4% percent of trials that started reached the finish line to date. In the past 5 years, 58 clinical trials started and 57 clinical trials were completed. i.e. 98.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Juravinski Cancer Centre" #1 sponsor was "Canadian Cancer Trials Group" with 43 trials, followed by "Ontario Clinical Oncology Group (OCOG)" with 43 trials sponsored, "National Cancer Institute (NCI)" with 42 trials sponsored, "NCIC Clinical Trials Group" with 41 trials sponsored and "Hoffmann-La Roche" with 41 trials sponsored. Other sponsors include 194 different institutions and companies that sponsored additional 98 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Juravinski Cancer Centre" #1 collaborator was "National Cancer Institute (NCI)" with 30 trials as a collaborator, "AstraZeneca" with 19 trials as a collaborator, "SWOG Cancer Research Network" with 12 trials as a collaborator, "Eastern Cooperative Oncology Group" with 10 trials as a collaborator and "NRG Oncology" with 10 trials as a collaborator. Other collaborators include 285 different institutions and companies that were collaborators in the rest 159 trials.

According to Clinical.Site data, the most researched conditions in "Juravinski Cancer Centre" are "Breast Cancer" (39 trials), "Prostate Cancer" (29 trials), "Ovarian Cancer" (12 trials), "Lung Cancer" (10 trials) and "Cancer" (9 trials). Many other conditions were trialed in "Juravinski Cancer Centre" in a lesser frequency.

Most popular intervention types in "Juravinski Cancer Centre" are "Drug" (280 trials), "Other" (83 trials), "Radiation" (59 trials), "Biological" (45 trials) and "Procedure" (29 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Laboratory Biomarker Analysis" (27 trials), "Paclitaxel" (15 trials), "Carboplatin" (14 trials) and "Quality-of-Life Assessment" (14 trials). Other intervention names were less common.

The vast majority of trials in "Juravinski Cancer Centre" are 264 trials for "All" genders, 76 trials for "Female" genders and 44 trials for "Male" genders.

Currently, there are 136 active trials in "Juravinski Cancer Centre". 2 are not yet recruiting, 48 are recruiting, 85 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 206 completed trials in Juravinski Cancer Centre, 1 suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Juravinski Cancer Centre, 56 "Phase 1" clinical trials were conducted, 153 "Phase 2" clinical trials and 144 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 38 trials that are defined as “Not Applicable".